eFFECTOR Therapeutics (EFTR) Competitors $0.0002 0.00 (-50.00%) As of 07/11/2025 02:14 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EFTR vs. CLVR, ONCSQ, PXMD, ATNFW, LBPSW, AEHAW, AIMDW, ALVOW, AMPE, and ACABWShould you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include Clever Leaves (CLVR), OncoSec Medical (ONCSQ), PaxMedica (PXMD), 180 Life Sciences (ATNFW), 4D pharma (LBPSW), Aesther Healthcare Acquisition (AEHAW), Ainos (AIMDW), Alvotech (ALVOW), Ampio Pharmaceuticals (AMPE), and Atlantic Coastal Acquisition Corp. II (ACABW). These companies are all part of the "pharmaceutical products" industry. eFFECTOR Therapeutics vs. Its Competitors Clever Leaves OncoSec Medical PaxMedica 180 Life Sciences 4D pharma Aesther Healthcare Acquisition Ainos Alvotech Ampio Pharmaceuticals Atlantic Coastal Acquisition Corp. II eFFECTOR Therapeutics (NASDAQ:EFTR) and Clever Leaves (NASDAQ:CLVR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations. Is EFTR or CLVR more profitable? Company Net Margins Return on Equity Return on Assets eFFECTOR TherapeuticsN/A N/A N/A Clever Leaves N/A N/A N/A Do institutionals & insiders have more ownership in EFTR or CLVR? 57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 6.9% of Clever Leaves shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 8.2% of Clever Leaves shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, EFTR or CLVR? Clever Leaves has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Clever Leaves, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioeFFECTOR TherapeuticsN/AN/A-$35.81M-$13.080.00Clever Leaves$17.42M0.00-$17.90M-$11.31N/A Does the media favor EFTR or CLVR? In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Clever Leaves'average media sentiment score. Company Overall Sentiment eFFECTOR Therapeutics Neutral Clever Leaves Neutral Which has more volatility and risk, EFTR or CLVR? eFFECTOR Therapeutics has a beta of 1, meaning that its share price has a similar volatility profile to the S&P 500.Comparatively, Clever Leaves has a beta of 3440.04, meaning that its share price is 343,904% more volatile than the S&P 500. SummaryClever Leaves beats eFFECTOR Therapeutics on 6 of the 7 factors compared between the two stocks. Get eFFECTOR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EFTR and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EFTR vs. The Competition Export to ExcelMetriceFFECTOR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1K$872.68M$5.61B$9.10BDividend YieldN/A4.84%5.24%4.00%P/E Ratio0.001.3828.1820.27Price / SalesN/A239.36428.6998.03Price / CashN/A17.6937.4658.16Price / Book0.006.588.045.49Net Income-$35.81M-$23.83M$3.19B$250.45M7 Day PerformanceN/A1.59%3.62%4.79%1 Month PerformanceN/A12.08%4.06%7.68%1 Year PerformanceN/A4.39%30.00%16.43% eFFECTOR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EFTReFFECTOR Therapeutics0.0822 of 5 stars$0.00-50.0%N/A-99.4%$1KN/A0.0010Gap DownCLVRClever LeavesN/A$0.00flatN/AN/A$1K$17.42M0.00560ONCSQOncoSec MedicalN/AN/AN/AN/A$1KN/A0.0040PXMDPaxMedicaN/A$0.00flatN/AN/A$1KN/A0.002News CoverageATNFW180 Life SciencesN/A$0.01+2.5%N/A-2.4%$0.00N/A0.007Positive NewsGap DownLBPSW4D pharmaN/AN/AN/AN/A$0.00$522K0.00N/AAEHAWAesther Healthcare AcquisitionN/A$0.01flatN/A-83.4%$0.00N/A0.002AIMDWAinosN/A$0.15flatN/A+70.4%$0.00$106.21K0.0040Gap UpALVOWAlvotechN/A$1.70+13.3%N/A-42.1%$0.00$585.60M0.004Positive NewsGap UpAMPEAmpio PharmaceuticalsN/A$0.00-96.3%N/A-99.9%$0.00N/A0.0020Gap DownACABWAtlantic Coastal Acquisition Corp. IIN/A$0.02-0.5%N/AN/A$0.00N/A0.0015 Related Companies and Tools Related Companies Clever Leaves Alternatives OncoSec Medical Alternatives PaxMedica Alternatives 180 Life Sciences Alternatives 4D pharma Alternatives Aesther Healthcare Acquisition Alternatives Ainos Alternatives Alvotech Alternatives Ampio Pharmaceuticals Alternatives Atlantic Coastal Acquisition Corp. II Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EFTR) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding eFFECTOR Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share eFFECTOR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EFTR Stock Alerts